Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles

9 Jan 2024

Abstract excerpt

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry proteomics in cerebrospinal fluid, based on 1,058 proteins, with different levels in individuals with AD (n = 419) compared to controls (n = 187). These AD subtypes had alterations in protein levels that were associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Immune cells in cancer
Share to Neuroinflammation and Neurodegeneration Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38195725
DOI: 10.1038/s43587-023-00550-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profilesPMID 38195725Read ↗

Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profilesSemantic proximity Read ↗

Proteomic Subtyping of Alzheimer’s Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic BiomarkersSemantic proximity Read ↗

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomicsSemantic proximity Read ↗

Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s diseaseSemantic proximity Read ↗

Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: A literature reviewSemantic proximity Read ↗

Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discoverySemantic proximity Read ↗

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomicsSemantic proximity Read ↗

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read ↗

Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuumSemantic proximity Read ↗

Multi-tissue proteomic signatures of Alzheimer’s disease: a systematic investigation in brain, CSF, blood and an exploratory study in tearsSemantic proximity Read ↗

Proteome-wide association study identifies novel Alzheimer's disease- associated proteinsSemantic proximity Read ↗

Multi-tissue proteomics identifies molecular signatures for sporadic and genetically defined Alzheimer disease casesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.